1st international consensus guidelines for advanced breast cancer (ABC 1) - Cardoso, F.; Costa, A.; Norton, L. (Breast, 2012)

Efficacy of eribulin in women with metastatic breast cancer: a pooled analysis of two phase 3 studies - Twelves, C.; Cortes, J.; Vahdat, L. (Breast Cancer Res Treat, 2014)

Induction of morphological and biochemical apoptosis following prolonged mitotic blockage by halichondrin B macrocyclic ketone analog E7389 - Kuznetsov, G.; Towle, M. J.; Cheng, H. (Cancer Res, 2004)

The primary antimitotic mechanism of action of the synthetic halichondrin E7389 is suppression of microtubule growth - Jordan, M. A.; Kamath, K.; Manna, T. (Mol Cancer Ther, 2005)

Inhibition of centromere dynamics by eribulin (E7389) during mitotic metaphase - Okouneva, T.; Azarenko, O.; Wilson, L. (Mol Cancer Ther, 2008)

Eribulin binds at microtubule ends to a single site on tubulin to suppress dynamic instability - Smith, J. A.; Wilson, L.; Azarenko, O. (Biochemistry, 2010)

Eribulin monotherapy versus treatment of physician’s choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study - Cortes, J.; O'Shaughnessy, J.; Loesch, D. (Lancet, 2011)

A phase II study of eribulin in Japanese patients with heavily pretreated metastatic breast cancer - Aogi, K.; Iwata, H.; Masuda, N. (Ann Oncol, 2012)

First-line treatment options for patients with her-2-negative metastatic breast cancer: the impact of modern adjuvant chemotherapy - Verma, S.; Mark, C. M. (Oncologist, 2007)

Design issues of randomized phase ii trials and a proposal for phase ii screening trials - Rubinstein, L. V.; Korn, E. L.; Freidlin, B. (J Clin Oncol, 2005)

Cytotoxic and hormonal treatment for metastatic breast cancer: a systematic review of published randomized trials involving 31,510 women - Fossati, R.; Confalonieri, C.; Torri, V. (J Clin Oncol, 1998)

Effect of chemotherapy on survival in metastatic breast cancer - Paterson, A. H.; Szafran, O.; Cornish, F. (Breast Cancer Res Treat, 1981)

Chemotherapy and survival in advanced breast cancer: the inclusion of doxorubicin in Cooper type regimens - A’Hern, R. P.; Smith, I. E.; Ebbs, S. R. (Br J Cancer, 1993)

Phase 2 study of eribulin mesylate as first-line therapy for locally recurrent or metastatic human epidermal growth factor receptor 2-negative breast cancer - McIntyre, K.; O'Shaughnessy, J.; Schwartzberg, L. (Breast Cancer Res Treat, 2014)

Impact of the number of prior chemotherapy regimens on outcomes for patients with metastatic breast cancer treated with eribulin: a post hoc pooled analysis - Cortes, J.; Twelves, C. (Breast J, 2020)

Effectiveness and safety of eribulin in Japanese patients with HER2-negative, advanced breast cancer: a 2-year post-marketing observational study in a real-world setting - Inoue, K.; Takahashi, M.; Mukai, H. (Invest New Drugs, 2020)

Real-life activity of eribulin mesylate among metastatic breast cancer patients in the multicenter national observational ESME program - Jacot, W.; Heudel, P. E.; Fraisse, J. (Int J Cancer, 2019)

Eribulin monotherapy in heavily pretreated metastatic breast cancer patients in real life - Sari, M.; Saip, P. (Indian J Cancer, 2020)

Eribulin mesylate or paclitaxel as first or second-line therapy in treating patients with recurrent stage iiic-iv breast cancer.

Significantly longer progression-free survival with nab-paclitaxel compared with docetaxel as first-line therapy for metastatic breast cancer - Gradishar, W. J.; Krasnojon, D.; Cheporov, S. (J Clin Oncol, 2009)

Real-world efficacy and safety of eribulin in advanced and pretreated HER2-negative breast cancer in a Spanish comprehensive cancer center - Sirvén, M. B.; Fernández-Ortega, A.; Stradella, A. (BMC Pharmacol Toxicol, 2019)